Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
By blocking NNMT, it may support cellular NAD+ levels and metabolic function
Other peptides under investigation Several additional peptides are being studied for disc-related applications, though with less established evidence: Vasoactive Intestinal Peptide (VIP) has demonstrated the ability to slow disc degeneration progression and improve aggrecan levels in mouse studies
Weight Loss Skinny Shots (MIC + B12) The Treatment Lipotropic injections combining methionine, inositol, choline, and B12 to boost metabolism and energy
This design choice introduces potential bias, particularly for subjective outcomes, but it reflects the practical reality that these treatments have different injection devices and titration schedules that would make blinding extremely difficult
Protocols That Work: How to Use BPC-157 for Arthritis Most clients want to know what a typical protocol looks like